Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David Jablons, MD
Maestro Clinical
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Chaoyang Hospital
Beijing, China
- Beijing Tumor Hospital
Beijing, China
- Beijing Youyi Hospital
Beijing, China
- China-Japan Friendship Hospital
Beijing, China
- Xuanwu Hospital
Beijing, China
- First Affiliated Hospital, Guangzhou Medical College
Guangzhou, China
- Sun Yat-Sen Cancer Center
Guangzhou, China
- Shanghai Chest Hopsital, Pulmonary Medicine
Shanghai, China
- Shanghai Lung Cancer Center, Shanghai Chest Hospital
Shanghai, China
- Shanghai Pulmonary Hospital
Shanghai, China
- Tianjin Cancer Center
Tianjin, China
- Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2009
- Primary completion
- 30 Sept 2012
- Completion
- 31 Dec 2012
- Last update posted
- 18 Dec 2013
- Registered enrollment
- 133
- Registry id
- NCT00883675
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.